Clinical Trials Browser

Active not recruiting × Lymphoma, Non-Hodgkin × Brentuximab Vedotin × Clear all

NCT01703949 2025-06-11

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin